101 results about "Cartilage damage" patented technology

To improve a cartilage replacement implant for the biological regeneration of a damaged cartilage area of articular cartilage in the human body, comprising a cell carrier which has a defect-contacting surface for placement on the damaged cartilage area and is formed and designed for colonization with human cells, so that after implantation of the cartilage replacement implant, formation of a gap between adjacent contact surfaces of the implant and surrounding recipient tissue is minimized, it is proposed that the cell carrier rest with surface-to-surface contact on a carrier and be joined to the carrier at a cell carrier surface that faces away from the defect-contacting surface. A method for producing a cartilage replacement implant is also proposed.

The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilagenous disorders, including degenerative cartilagenous disorders such as arthritis, comprising the administration of IL-17 and/or LIF antagonists (e.g., anti-IL-17 and anti-LIF antibodies). Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilagenous disorders comprising the administration of IL-17 or LIF antagonists in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of IL-17 and/or LIF antagonist. Alternatively, the method provides for the treatment of a mammal suffering from a cartilagenous disorder, comprising the adminstration of a therapeutically effective amount of an IL-17 and/or LIF antagonist.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The present invention relates to a medical composite biomaterial. More specifically, the present invention relates to a medical composite biomaterial including collagen and a hyaluronic acid derivative. Also, the present invention relates to a cartilage cell treating agent using the biomaterial and stem cells derived from a mammal umbilical cord. The biomaterial does not cause an immune reaction, has superior durability, and the cartilage cell treating agent comprising the biomaterial and the stem cells enables arthroscopic surgery, thereby reducing pain of the patient and effectively treat of degenerative arthritis and cartilage damage.

A method for modulating enzymatic degradation of articular cartilage in a dog comprises administering to the dog an enzymatic degradation modulating effective amount of eicosapentaenoic acid (EPA), for example as a component of a food composition. By practice of the method in a dog having arthritis, mobility of the dog can be increased, weight bearing in an arthritic limb can be increased, and/or pain associated with arthritis can be reduced.

The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired. And the polymers of the composition of the present invention have one or more characteristics among the biocompatibility, biodegradation property and possible ability to serve to enhance nutrition of cells and possible ability to enhance formation of intercellular substrate as well as the mechanical strength and flexibility to the degree which is proper for cellular transplantation and generation of cartilage tissues.

The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.

The invention discloses a preparation technology of biphasic bone and cartilage tissue engineering scaffold material. Firstly chitosan and collagen powder are added into acetate solution and laid in a refrigerator to be preserved; then PLA solution is prepared, and bone dust is put into the PLA solution and is uniformly mixed and stirred; then prepared PLA/bone dust solution is injected into a die to be prefrozen; then collagen/chitosan solution is added into the prefrozen die to be prefrozen, and a scaffold sample is obtained after freeze drying; and finally the bone and cartilage biphasic scaffold conducted to freeze drying is taken out from the die. The preparation technology ensures that a bone layer scaffold has the hardness and the strength approximate to that of natural bone tissue, is not only beneficial to the repair of cartilage tissue, but also convenient for clinically operating and fixing the scaffold; and meanwhile, a cartilage layer scaffold is provided with a multilayer structure containing perpendicular pore canals, is convenient for guiding cells on the scaffold to grow at a state close to that of a natural cartilage laminated structure, and improves the injury repair effect of cartilage.

Systems and methods are described for treating osteochondral pathologies. An implantable prosthesis for treating osteochondral pathologies includes: a porous substrate; and a substance positioned within the porous substrate that is elutable with regard to the porous substrate. The systems and methods provide advantages because a baited route is provided to attract mesenchymal stem cells from the cancellous bone underlying the articular surfaces up to chondral lesions within the joint, thereby promoting the growth of chondrocytes in the area of the chondral lesions.

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

The invention belongs to the technical field of cartilage complexes, in particular to preparation of multilayer cartilage complex containing cytokine microspheres through electrospinning 3D printing,which comprises the following steps of: S1, culturing seed cells; S2, preparing a three-phase integrated scaffold; S3, planting cells. According to the method, an electrostatic spinning 3D printing technology is adopted, the fiber diameter and the printing path can be accurately controlled, the diameter of a monofilament can be as fine as 10 micrometers, corresponding loaded cytokine microspheresare mixed in a printing material to be loaded on a printed bracket, by controlling the types and contents of the cytokines, the corresponding seed cells can be induced to differentiate to the corresponding cells on the scaffold layer by layer so as to finally form a component hierarchical structure similar to a normal cartilage tissue, the complex has a layered structure similar to the normal articular cartilage tissue, and has high structural precision; and the loaded cytokine is favorable for promoting cell proliferation and differentiation, and is favorable for repairing cartilage damage.

Described herein are orthopedic applications of mesenchymal stem cell encapsulated and delivered for treatment of cartilage damage in joints. A therapeutic composition is prepared comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in microbeads of a three-dimensional biocompatible gel matrix. The hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The microbeads are implanted adjacent a target orthopedic treatment site where the microbeads allow the release of cellular factors from the encapsulated stem cells to surrounding orthopedic tissues to achieve desired therapeutic results such as healing of cartilage damage in joints.

The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula

and pharmaceutically acceptable salts thereof, wherein R₁ is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

The present invention relates to the application of nucleic acid therapy for the repair and regeneration of cartilage. The invention encompasses the introduction of naked DNA encoding bioactive agent(s), whose expression stimulates and otherwise facilitates the repair and regeneration of cartilage. The present invention provides DNA constructs for introduction to the site of cartilage damage. Pharmaceutical compositions comprising nucleic acid encoding one or more bioactive factor, optionally with a matrix or polymer, are provided. Methods for expression of bioactive agent(s) are provided. Methods for enhancing cartilage repair and/or regeneration comprising introduction of bioactive factors as naked DNA are further provided. Methods for the treatment or prevention of cartilage damage in various orthopaedic and rheumatologic conditions are provided.

The invention discloses a cell gel preparation for treating articular cartilage injury and a use thereof, and a used gel solution for maintaining the activity of cryopreserved cells. The formula of the cell gel preparation comprises, according to the volume percentage, 50% to 95%, of the gel solution and 5% to 50% of a compound electrolyte cell resuspension, and per milliliter of the cell gel preparation contains 0.5*10<5>-2*10<7> cells. The gel solution includes the following components by mass and volume: 1 to 50 mg of a high molecular material stabilizer, 0.1 to 1 mg of chondroitin sulfate,5 to 50 mg of human serum albumin, 30 to 150 [mu]l of glycerol, 1 to 30 [mu]l of DMSO, and 700 to 900 [mu]l of a compound electrolyte injection liquid or amino acid injection liquid or normal salineinjection liquid. The gel preparation has good biocompatibility and can be directly stored at low temperature for a long time and maintain high cell viability, and does not require traditional liquidnitrogen cryopreservation; the cell gel preparation after resuscitation can maintain cell biological characteristics and functions and high survival rate in a joint cavity, and can be used in treatment of articular cartilage injury.

The present invention provides a novel active ingredient which can be safely used in preventing, ameliorating or treating diseases related to the cartilage such as cartilage damages and cartilage disorders. Since the egg yolk protein hydrolyzate has an effect on chondrocyte proliferation promotion, it is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating joint pain. The egg yolk protein hydrolyzate is a natural-origin material with high safety and, therefore, can be widely used in foods and drinks, medicines, feeds and the like which can be daily ingested.

The invention relates to an articular cartilage repairing material based on oxidized hyaluronic acid-type II collagen and autologous concentration bone marrow nucleated cells and a preparation method.The articular cartilage repairing material is prepared from oxidized hyaluronic acid, type II collagen and autologous concentration bone marrow nucleated cells; the autologous concentration bone marrow nucleated cells in the material have potential in self-renewal and chondrogenic differentiation, participate in cartilage defect repairing, and thus realize a perfect cartilage defect repairing effect; the repaired tissue appears like hyaline cartilage and is obviously superior to the blank control group in surface flatness, integration degree with adjacent normal cartilage, content of type IIcollagen, GAG content, forms of calcified cartilage and subchondral bone and the like, and has potential in clinical transformation.